Latest News

November 2014
Celtaxsys Announces Sanjeev Ahuja as Chief Medical Officer read more »

October 2014
Celtaxsys presenting at 2014 North American Cystic Fibrosis Foundation annual meeting read more »

Turning down inflammatory response.
Opening up new treatment possibilities.

The body goes to great lengths to maintain a delicate balance between inflammation and immunity.
Too much immune cell activity leads to tissue-destroying inflammatory diseases. Too little immune cell activity leads to infection. Celtaxsys is taking an entirely new approach to inflammatory disease. By developing treatments that reduce inflammation in a tunable manner we are working to bring new hope to patients who suffer from Cystic Fibrosis, Gout, Acne and other life-altering diseases.


Drug Pipeline

Our leading drug candidate, orally administered CTX-4430, completed a 96-subject Phase 1 clinical trial in August, 2013 and is currently in a Phase 1B trial in adult Cystic Fibrosis patients. Following completion of the Phase 1 program, oral CTX-4430 will enter Phase 2 trials for Adult Cystic Fibrosis,Gout and Acne. 

more about our Drug Pipeline

A Breath of Fresh Air: Treating Cystic Fibrosis

Cystic fibrosis (CF) is an inherited chronic disease that affects the lungs and digestive system of about 70,000 children and adults worldwide (30,000 in the US). CTX-4430 uses a novel approach to reduce airway obstruction by blocking excessive white blood cell influx. By blocking white blood cell influx and activation, CTX-4430 reduces airway degradation caused by inflammation.

more about our program in CF

Putting out the Fire: Treatment and Prevention of Gout Flares

Gout is a metabolic disorder where uric acid builds up in the blood until it settles into joints and other areas in the form of solid crystals. At some point, these crystals produce an inflammatory signal that causes certain immune cells called neutrophils to gather. Neutrophils are responsible for swelling, redness, pain and are the primary source of the tissue-destructive factors that lead to disability and disfigurement. CTX-4430 is a unique oral drug aimed specifically at treating the inflammation caused by neutrophils in gout. Reducing inflammation is expected to ease pain, prevent future attacks and reduce long-term damage to joints.

more about our program in Gout

Clearly Different: Treatment of Acne Vulgaris

Acne denotes a family of chronic inflammatory skin conditions characterized by pustules (raised red lesions containing fluid) and papules (raised red lesions without fluid), which can cause long-term damage and scarring. Thus, treating inflammation is a major goal of acne therapy. CTX-4430 works by blocking inflammation at its source, preventing formation of an inflammatory signal called Leukotriene B4 (LTB4). Doing so is expected to yield the following benefits: Decreased swelling and redness of existing acne lesions, reduced the formation of new lesions, and limited tissue damage that leads to scarring.

more about our program in Acne Vulgaris

About Celtaxsys

Celtaxsys is a clinical-stage development company focused on novel therapeutics that treat inflammatory disease through regulation of immune cell migration and activation. Our lead drug candidate, CTX-4430, is a potent, oral, once-daily, small-molecule LTA4 Hydrolase (LTA4H) inhibitor – the key enzyme in production of the powerful promoter of inflammation Leukotriene B4 (LTB4).  Both LTA4H and LTB4 are strongly implicated in the pathogenesis of pulmonary inflammation in Cystic Fibrosis (CF). CTX-4430 has been shown to be effective in several CF-related, pre-clinical models and has been well tolerated in healthy volunteers and CF patients. 

Latest News

Celtaxsys Announces Sanjeev Ahuja as Chief Medical Officer
Celtaxsys, Inc. is pleased to announce the appointment of Sanjeev Ahuja, MD, MBA, FACP as Chief Medical Officer, effective November 1, 2014.
see press release here

Celtaxsys presenting at 2014 North American Cystic Fibrosis Foundation annual meeting
Celtaxsys, Inc. a privately held biotechnology company announced today that new data on their lead compound, once daily, oral CTX-4430 will be presented at the 2014 North American Cystic Fibrosis Foundation annual meeting, October 9-12
see press release here

For More Celtaxsys News please click here